What is ARTBIO?
Headquartered in Cambridge, Massachusetts, ARTBIO is at the forefront of the radiopharmaceutical revolution. The company specializes in the creation of alpha radioligand therapies (ART), a sophisticated class of cancer treatments that deliver targeted radiation directly to tumor cells while minimizing damage to healthy tissue. By integrating advanced scientific research with a robust operational ecosystem, ARTBIO is positioning itself as a leader in the precision oncology market. The company's strategic focus remains on scaling its manufacturing capabilities and accelerating clinical trials to bring transformative, life-saving solutions to patients globally.
How much funding has ARTBIO raised?
ARTBIO has raised a total of $245M across 3 funding rounds:
Angel/Seed
$23M
Series A
$90M
Series B
$132M
Angel/Seed (2023): $23M with participation from F-Prime Capital Partners
Series A (2023): $90M led by Omega Fund Management, F-Prime Capital Partners, and Third Rock Ventures
Series B (2025): $132M supported by Sofinnova Partners, B Capital Group, Omega Fund Management, F-Prime Capital, Alexandria, Qatar Investment Authority, and Third Rock Ventures
Key Investors in ARTBIO
Sofinnova Partners
A leading European venture capital firm in life sciences, Sofinnova Partners specializes in healthcare and sustainability, acting as a hands-on builder across the entire value chain of life sciences investments.
B Capital Group
B Capital is a global venture capital firm that empowers entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
Third Rock Ventures
A healthcare venture firm focused on disruptive areas of science and medicine, Third Rock Ventures combines scientific vision and operational expertise to launch companies that make a dramatic difference in patients' lives.
What's next for ARTBIO?
With the successful closure of this latest financing, ARTBIO is well-positioned to advance its clinical pipeline and expand its infrastructure. The capital will likely be deployed to scale the production of its alpha-emitting isotopes and support the expansion of its research facilities in Cambridge. As the company moves into its next phase of growth, the focus will shift toward executing pivotal clinical trials and establishing strategic partnerships that enhance its market reach. The backing from a diverse group of life sciences investors provides the necessary runway to navigate the complex regulatory landscape and solidify its competitive advantage in the rapidly evolving field of targeted cancer therapeutics.
See full ARTBIO company page
